Indoco Remedies
Indoco Remedies Ltd., a prominent player in the pharmaceutical industry, is headquartered in Mumbai, India. Established in 1945, the company has made significant strides in the development and manufacturing of a diverse range of pharmaceutical products, including formulations and active pharmaceutical ingredients (APIs). With a strong presence in both domestic and international markets, Indoco Remedies operates in various regions, focusing on key therapeutic areas such as anti-infectives, cardiovascular, and central nervous system disorders. Renowned for its commitment to quality and innovation, Indoco Remedies has achieved several milestones, including regulatory approvals from major global health authorities. The company’s core offerings are distinguished by their adherence to stringent quality standards and a robust research and development framework. As a result, Indoco Remedies has established a solid market position, recognised for its reliability and excellence in the pharmaceutical sector.
DitchCarbon Score
How does Indoco Remedies's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Indoco Remedies's score of 23 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Indoco Remedies's reported carbon emissions
In 2024, Indoco Remedies reported total carbon emissions of approximately 51,356,840 kg CO2e, comprising 14,786,810 kg CO2e from Scope 1 and 36,554,030 kg CO2e from Scope 2. This represents a slight increase in emissions compared to 2023, where the company recorded about 57,766,030 kg CO2e, with 12,827,330 kg CO2e from Scope 1 and 44,543,700 kg CO2e from Scope 2. The emissions intensity for Scope 1 and Scope 2 combined was approximately 0.000611 INR per rupee of turnover in 2024, compared to 0.000734 INR in 2023. This indicates a focus on improving efficiency relative to revenue, despite the overall increase in emissions. Indoco Remedies has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of Scope 3 emissions data suggests that the company may be in the early stages of addressing its full carbon footprint. Overall, Indoco Remedies is actively monitoring its emissions and working towards enhancing its sustainability practices within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 12,827,330 | 00,000,000 | 00,000,000 |
| Scope 2 | 44,543,700 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Indoco Remedies is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
